Diamond Biotechnology Co., Ltd
Diamond Biotechnology Co., Ltd researches, develops, manufactures, and sells medical equipment and skincare products in Taiwan and internationally. The company offers skin care products under the Timera and Diamond Beauty brands. It also leases medical equipment. Diamond Biotechnology Co., Ltd was founded in 2014 and is based in Taipei, Taiwan.
Diamond Biotechnology Co., Ltd (6815) - Net Assets
Latest net assets as of June 2025: NT$617.26 Million TWD
Based on the latest financial reports, Diamond Biotechnology Co., Ltd (6815) has net assets worth NT$617.26 Million TWD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$981.82 Million) and total liabilities (NT$364.55 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$617.26 Million |
| % of Total Assets | 62.87% |
| Annual Growth Rate | 5.87% |
| 5-Year Change | 168.34% |
| 10-Year Change | N/A |
| Growth Volatility | 41.26 |
Diamond Biotechnology Co., Ltd - Net Assets Trend (2019–2024)
This chart illustrates how Diamond Biotechnology Co., Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Diamond Biotechnology Co., Ltd (2019–2024)
The table below shows the annual net assets of Diamond Biotechnology Co., Ltd from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$623.05 Million | +79.87% |
| 2023-12-31 | NT$346.39 Million | +14.44% |
| 2022-12-31 | NT$302.69 Million | +10.83% |
| 2021-12-31 | NT$273.11 Million | +17.62% |
| 2020-12-31 | NT$232.19 Million | -50.43% |
| 2019-12-31 | NT$468.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Diamond Biotechnology Co., Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 38.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | NT$76.36 Million | 12.26% |
| Common Stock | NT$337.94 Million | 54.24% |
| Other Components | NT$208.75 Million | 33.50% |
| Total Equity | NT$623.05 Million | 100.00% |
Diamond Biotechnology Co., Ltd Competitors by Market Cap
The table below lists competitors of Diamond Biotechnology Co., Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tamilnadu PetroProducts Limited
NSE:TNPETRO
|
$45.16 Million |
|
Crescendo Corporation Bhd
KLSE:6718
|
$45.17 Million |
|
Euro Yatirim Holding AS
IS:EUHOL
|
$45.18 Million |
|
China Starch Holdings Limited
PINK:CHNSF
|
$45.18 Million |
|
Sungchang Hold
KO:000180
|
$45.15 Million |
|
Holiday Entertainment Co Ltd
TW:9943
|
$45.14 Million |
|
Cube Entertainment Inc
KQ:182360
|
$45.13 Million |
|
SYN-Tech Chem & Pharm Co Ltd
TWO:1777
|
$45.13 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Diamond Biotechnology Co., Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 346,394,000 to 623,051,000, a change of 276,657,000 (79.9%).
- Net income of 73,198,000 contributed positively to equity growth.
- Dividend payments of 4,950,000 reduced retained earnings.
- Share repurchases of 1,385,000 reduced equity.
- New share issuances of 221,000,000 increased equity.
- Other comprehensive income increased equity by 59,000.
- Other factors decreased equity by 11,265,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$73.20 Million | +11.75% |
| Dividends Paid | NT$4.95 Million | -0.79% |
| Share Repurchases | NT$1.39 Million | -0.22% |
| Share Issuances | NT$221.00 Million | +35.47% |
| Other Comprehensive Income | NT$59.00K | +0.01% |
| Other Changes | NT$-11.27 Million | -1.81% |
| Total Change | NT$- | 79.87% |
Book Value vs Market Value Analysis
This analysis compares Diamond Biotechnology Co., Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.23x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.06x to 2.23x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$10.90 | NT$44.20 | x |
| 2020-12-31 | NT$8.62 | NT$44.20 | x |
| 2021-12-31 | NT$9.81 | NT$44.20 | x |
| 2022-12-31 | NT$10.87 | NT$44.20 | x |
| 2023-12-31 | NT$11.12 | NT$44.20 | x |
| 2024-12-31 | NT$19.86 | NT$44.20 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Diamond Biotechnology Co., Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 11.75%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.53%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.70x
- Recent ROE (11.75%) is below the historical average (12.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 17.64% | 16.46% | 0.57x | 1.88x | NT$19.14 Million |
| 2020 | 4.76% | 3.61% | 0.70x | 1.89x | NT$-12.17 Million |
| 2021 | 15.35% | 10.61% | 0.73x | 1.98x | NT$14.61 Million |
| 2022 | 11.03% | 7.68% | 0.69x | 2.08x | NT$3.12 Million |
| 2023 | 13.49% | 7.59% | 0.77x | 2.31x | NT$12.10 Million |
| 2024 | 11.75% | 9.53% | 0.73x | 1.70x | NT$10.89 Million |
Industry Comparison
This section compares Diamond Biotechnology Co., Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,188,209,400
- Average return on equity (ROE) among peers: 10.09%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Diamond Biotechnology Co., Ltd (6815) | NT$617.26 Million | 17.64% | 0.59x | $45.16 Million |
| Health & Life Co., Ltd. (1781) | $393.05 Million | 6.17% | 1.08x | $12.92 Million |
| Hi-Clearance (1788) | $3.00 Billion | 11.98% | 0.65x | $104.25 Million |
| Radiant Innovation (3373) | $865.89 Million | -3.30% | 0.08x | $18.76 Million |
| Wellell Inc (4106) | $458.47 Million | 22.17% | 0.32x | $37.12 Million |
| Rossmax International Ltd (4121) | $1.66 Billion | 8.16% | 1.02x | $34.41 Million |
| United Orthopedic (4129) | $2.22 Billion | 5.87% | 0.94x | $279.97 Million |
| Dynamic Medical Technologies (4138) | $1.70 Billion | 12.34% | 0.81x | $39.16 Million |
| Ok Biotech Co Ltd (4155) | $452.10 Million | 21.38% | 0.72x | $44.61 Million |
| Bioptik Technology (4161) | $824.15 Million | 10.40% | 0.82x | $30.48 Million |
| EPS Bio Technology Corp. (4183) | $304.55 Million | 5.68% | 0.78x | $4.27 Million |